Some of these pathways emerged also in our studies, using a phospho-kinase array, that showed the active involvement of eight phosphorylated kinases (EGFR, p38α, Src, Lyn, STAT2, STAT6, STAT5a/b and c-Jun), in early processes associated with cell motility and invasiveness which can be modulated by gefitinib despite tumor progression. This evidence concerns the gene STAT5A and neoplasm.